Abstract:The persistence of increased excitability and spontaneous activity in injured peripheral neurons is imperative for the development and persistence of many forms of neuropathic pain. This aberrant activity involves increased activity and/or expression of voltage-gated Na + and Ca 2+ channels and hyperpolarization activated cyclic nucleotide gated (HCN) channels as well as decreased function of K + channels. Because they display limited central side effects, peripherally restricted Na + and Ca 2+ channel blockers and K + channel activators offer potential therapeutic approaches to pain management. This review outlines the current status and future therapeutic promise of peripherally acting channel modulators. Selective blockers of Na v 1.3, Na v 1.7, Na v 1.8, Ca v 3.2, and HCN2 and activators of K v 7.2 abrogate signs of neuropathic pain in animal models. Unfortunately, their performance in the clinic has been disappointing; some substances fail to meet therapeutic end points whereas others produce dose-limiting side effects. Despite this, peripheral voltage-gated cation channels retain their promise as therapeutic targets. The way forward may include (i) further structural refinement of K + channel activators such as retigabine and ASP0819 to improve selectivity and limit toxicity; use or modification of Na + channel blockers such as vixotrigine, PF-05089771, A803467, PF-01247324, VX-150 or arachnid toxins such as Tap1a; the use of Ca 2+ channel blockers such as TTA-P2, TTA-A2, Z 944, ACT709478, and CNCB-2; (ii) improving methods for assessing “pain” as opposed to nociception in rodent models; (iii) recognizing sex differences in pain etiology; (iv) tailoring of therapeutic approaches to meet the symptoms and etiology of pain in individual patients via quantitative sensory testing and other personalized medicine approaches; (v) targeting genetic and biochemical mechanisms controlling channel expression using anti-NGF antibodies such as tanezumab or re-purposed drugs such as vorinostat, a histone methyltransferase inhibitor used in the management of T-cell lymphoma, or cercosporamide a MNK 1/2 inhibitor used in treatment of rheumatoid arthritis; (vi) combination therapy using drugs that are selective for different channel types or regulatory processes; (vii) directing preclinical validation work toward the use of human or human-derived tissue samples; and (viii) application of molecular biological approaches such as clustered regularly interspaced short palindromic repeats (CRISPR) technology.

Sodium Channel Inhibitors (Nav1.7, 1.8, And 1.9) For Neuropathic Pain Management

The physiological function of different voltage-gated sodium channels in pain

Recent advances in small molecule Nav 1.7 inhibitors for cancer pain management

Analgesic potential of voltage gated sodium channel modulators for the management of pain

Unique electrophysiological property of a novel Nav1.7, Nav1.8, and Nav1.9 sodium channel blocker, ANP-230

Interplay of Nav1.8 and Nav1.7 channels drives neuronal hyperexcitability in neuropathic pain

Computational modeling to study the impact of changes in Nav1.8 sodium channel on neuropathic pain

Progress in the Study of Voltage-Gated Sodium Channel Nav1.7 in Pain

Differential Inhibition of Nav1.7 and Neuropathic Pain by Hybridoma-Produced and Recombinant Monoclonal Antibodies that Target Nav1.7

Drug discovery targeting Nav1.8: Structural insights and therapeutic potential

Peripheral Voltage-Gated Cation Channels in Neuropathic Pain and Their Potential as Therapeutic Targets

Insights into the voltage-gated sodium channel, NaV1.8, and its role in visceral pain perception

Research Advance in Sodium Channels Involved in Neuropathic Pain

Differential Inhibition of Nav1.7 and Neuropathic Pain by Hybridoma-Produced and Recombinant Monoclonal Antibodies That Target Nav1.7 : Differential Activities of Nav1.7-targeting Monoclonal Antibodies.

Use-Dependent Relief of Inhibition of Nav1.8 Channels by A-887826

Specific Subunits of Voltage-Gated Sodium Channel Underlying the Subthreshold Membrane Potential Oscillations: Potential Therapeutic Targets for Neuropathic Pain

Nanomedicine and voltage-gated sodium channel blockers in pain management: a game changer or a lost cause?

Discovery of E0199: A Novel Compound Targeting Both Peripheral NaV and KV7 Channels to Alleviate Neuropathic Pain

Selective Voltage-Gated Sodium Channel Peptide Toxins from Animal Venom: Pharmacological Probes and Analgesic Drug Development

Nav1.7 Modulator Bearing a 3-Hydroxyindole Backbone Holds the Potential to Reverse Neuropathic Pain

Persistent (Nav1.9) sodium currents in human dorsal root ganglion neurons